Table 4 Changes in exercise testing after a 3-week combination therapy with ghrelin and dietary medium-chain triglycerides (N = 10)

6-MWD, m

304 (104)

347 (99)^*

351 (107)^*

CPET, at peak exercise

 \( V_{{{\text{O}}_{2} }}^{{\prime }} \), mL/min/kg

10.9 (2.6)

11.5 (2.2)

11.8 (2.2)

 \( V_{{{\text{O}}_{2} }}^{{\prime }} \), mL/min

495.1 (109.6)

543.1 (122.8)

562.3 (109.1)^*

 Endurance time, s

333 (157)

400 (112)^**

389 (107)^*

 Dyspnea (Borg scale)

5.7 (1.2)

6.5 (1.8)

5.8 (2.0)

 Leg discomfort (Borg scale)

4.8 (2.6)

4.1 (2.3)

3.9 (2.6)

 V_T, L

0.86 (0.17)

0.92 (0.14)

0.95 (0.14)

 f_R, breaths/min

30 (7)

30 (6)

28 (6)

 V′_E, L/min

24.9 (6.1)

28.0 (7.7)^*

26.6 (7.3)

 \( \Delta {\text{F}}_{{{\text{O}}_{ 2} }} \),  %

2.48 (0.40)

2.41 (0.26)

2.62 (0.34)^†

0.0349

 V_D/V_T

0.43 (0.06)

0.44 (0.03)

0.43 (0.05)

0.6099

 V′_E/\( V_{{{\text{O}}_{2} }}^{{\prime }} \)

50.7 (7.9)

51.4 (5.4)

47.1 (6.8)^*††

 V′_E/\( V_{{{\text{CO}}_{2} }}^{{\prime }} \)

50.8 (6.9)

49.1 (4.9)

47.7 (6.3)

 R

1.00 (0.07)

1.05 (0.09)^**

0.99 (0.08)^†††

 HR, beats/min

114 (20)

121 (20)^*

116 (19)

 O₂ pulse, mL/beats

4.3 (0.5)

4.5 (0.6)

4.9 (0.8)^**†

 SpO₂,  %

90.7 (5.7)

89.5 (3.7)

91.0 (4.0)